Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus(T2DM)
Conditions
Type 2 Diabetes Mellitus(T2DM)
Trial Timeline
Feb 1, 2013 → Apr 1, 2013
NCT ID
NCT01755494About Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mg
Saxagliptin 5 mg + Metformin XR 500 mg + Mertformin XR 2 x 500 mg + Komboglyze XR 5/500 mg + Komboglyze XR 5/1000 mg is a phase 1 stage product being developed by AstraZeneca for Type 2 Diabetes Mellitus(T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT01755494. Target conditions include Type 2 Diabetes Mellitus(T2DM).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01755494 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus(T2DM)